TABLE 4.
Psychiatric symptoms
| Variable | GBA PD BL Visit, N = 80 | LRRK2 PD BL Visit, N = 158 | sPD Year 2 Visit, N = 361 | P Values | |||
|---|---|---|---|---|---|---|---|
| GBA vs. LRRK2 | GBA vs. sPD | LRRK2 vs. sPD | |||||
| GDS | 0.6959 | 0.4957 | 0.1494 | ||||
| Mean (SD) | 3.0 (3.0) | 3.1 (3.1) | 2.7 (2.9) | ||||
| Missing | 3 | 5 | 1 | ||||
| Categorical GDS | 0.1872 | 0.9184 | 0.0762 | ||||
| Depressed, >4, n (%) | 14 (18.2%) | 40 (26.1%) | 65 (18.1%) | ||||
| Missing | 3 | 5 | 1 | ||||
| STAI state subscore | 0.5655 | 0.4298 | 0.0647 | ||||
| Mean (SD) | 33.7 (9.8) | 34.6 (10.6) | 32.6 (10.0) | ||||
| Missing | 3 | 4 | 0 | ||||
| STAI trait subscore | 0.5934 | 0.1298 | 0.0065 | ||||
| Mean (SD) | 34.6 (10.0) | 35.4 (10.2) | 32.6 (9.3) | ||||
| Missing | 3 | 5 | 0 | ||||
| Any QUIP disorder | 0.6184 | 0.0004a | 0.0002a | ||||
| Any 1 or more disorders, n (%) | 31 (40.3) | 54 (35.3) | 73 (20.2) | ||||
| Missing | 3 | 5 | 0 | ||||
| MDS-UPDRS part II, apathy | 0.1834 | 0.0696 | 0.6373 | ||||
| Normal, n (%) | 66 (82.5) | 118 (75.6) | 264 (73.1) | ||||
| Slight, n (%) | 10 (12.5) | 30 (19.2) | 62 (17.2) | ||||
| Mild, n (%) | 4 (5.0) | 5 (3.2) | 27 (7.5) | ||||
| Moderate, n (%) | 0 (0.0) | 2(1.3) | 7(1.9) | ||||
| Severe, n (%) | 0 (0.0) | 1 (0.6) | 1 (0.3) | ||||
| Missing | 0 | 2 | 0 | ||||
| MDS-UPDRS part II, hallucinations and psychosis | 0.8826 | 0.9533 | 0.9034 | ||||
| Normal, n (%) | 73 (91.3) | 144 (92.3) | 335 (92.8) | ||||
| Slight, n (%) | 6 (7.5) | 10 (6.4) | 22 (6.1) | ||||
| Mild, n (%) | 1 (1.3) | 2(1.3) | 3 (0.8) | ||||
| Moderate, n (%) | 0 (0.0) | 0 (0.0) | 1 (0.3) | ||||
| Severe, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||||
| Missing | 0 | 2 | 0 | ||||
| Antidepressants, yes, n (%) | 22 (27.5) | 38 (24.1) | 90 (24.9) | 0.4812 | 0.6817 | 0.6381 | |
| Antipsychotics, yes, n (%) | 1 (1.3) | 1 (0.6) | 2 (0.6) | 0.8387 | 0.4259 | 0.3079 | |
| Anxiolytics-hypnotics, yes, n (%) | 17 (21.3) | 38 (24.1) | 64 (17.7) | 0.6403 | 0.5524 | 0.1531 | |
Significance defined at P < 0.0017.
Report generated on data submitted as of July 1, 2019. P values were found using linear or logistic regression models adjusting for gender and disease duration. For QUIP, the models also adjusted for LED calculated for dopamine agonists class of drugs. For apathy and hallucinations, we are modeling “normal” versus everything else.
GBA, glucosylceramidase beta; PD, Parkinson’s disease; LRRK2, leucine rich kinase 2; sPD, sporadic PD; BL, baseline; GDS, Geriatric Depression Scale; SD, standard deviation; STAI, State-Trait Anxiety Inventory; QUIP, Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease; MDS-UPDRS, Movement Disorders Society Unified Parkinson’s Disease Rating Scale.